Vericel Co. (NASDAQ:VCEL) Shares Sold by Amalgamated Bank

Amalgamated Bank lowered its stake in shares of Vericel Co. (NASDAQ:VCEL) by 1.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,649 shares of the biotechnology company’s stock after selling 279 shares during the quarter. Amalgamated Bank’s holdings in Vericel were worth $672,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Vericel by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock worth $177,567,000 after acquiring an additional 39,349 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Vericel by 1.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,031,940 shares of the biotechnology company’s stock valued at $47,346,000 after buying an additional 10,245 shares during the last quarter. William Blair Investment Management LLC boosted its stake in shares of Vericel by 7.9% during the 2nd quarter. William Blair Investment Management LLC now owns 908,141 shares of the biotechnology company’s stock valued at $41,666,000 after buying an additional 66,464 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Vericel by 34.9% during the 2nd quarter. Federated Hermes Inc. now owns 840,787 shares of the biotechnology company’s stock valued at $38,575,000 after acquiring an additional 217,437 shares in the last quarter. Finally, Congress Asset Management Co. MA raised its position in shares of Vericel by 509.1% during the 1st quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock valued at $43,514,000 after acquiring an additional 699,147 shares in the last quarter.

Vericel Stock Down 2.0 %

Shares of VCEL stock opened at $43.19 on Friday. Vericel Co. has a 12 month low of $30.18 and a 12 month high of $54.10. The firm has a market cap of $2.10 billion, a PE ratio of -4,319.00 and a beta of 1.67. The stock has a 50 day moving average of $47.63 and a 200-day moving average of $47.38.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $52.70 million for the quarter, compared to analysts’ expectations of $52.59 million. Vericel had a return on equity of 0.35% and a net margin of 0.37%. Vericel’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.11) earnings per share. As a group, equities analysts predict that Vericel Co. will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling at Vericel

In other news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $51.40, for a total transaction of $899,500.00. Following the sale, the chief executive officer now owns 220,937 shares in the company, valued at $11,356,161.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $51.40, for a total transaction of $899,500.00. Following the transaction, the chief executive officer now owns 220,937 shares of the company’s stock, valued at $11,356,161.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sean C. Flynn sold 15,000 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $52.18, for a total value of $782,700.00. Following the transaction, the insider now directly owns 707 shares in the company, valued at approximately $36,891.26. The disclosure for this sale can be found here. Insiders have sold 38,045 shares of company stock worth $1,956,725 over the last three months. Company insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

VCEL has been the topic of several research reports. Canaccord Genuity Group assumed coverage on Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 price target on the stock. HC Wainwright raised their price target on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, August 2nd. BTIG Research lowered their price target on Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, July 15th. Truist Financial raised their price target on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Finally, TD Cowen raised their target price on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $55.75.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.